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Background-—Women with a history of preeclampsia are at increased risk of cardiovascular morbidity and mortality. However, the
underlying mechanisms of disease association, and the ideal method of monitoring this high-risk group, remains unclear. This
review aims to determine whether women with a history of preeclampsia show clinical or subclinical cardiac changes when
evaluated with an echocardiogram.
Methods and Results-—A systematic search of MEDLINE, EMBASE, and CINAHL databases was performed to identify studies that
examined cardiac function in women with a history of preeclampsia, in comparison with those with normotensive pregnancies. In the
27 included studies, we found no significant differences between preeclampsia and nonpreeclampsia women with regard to left
ventricular ejection fraction, isovolumetric relaxation time, or deceleration time. Women with a history of preeclampsia demonstrated
a higher left ventricular mass index and relative wall thickness with a mean difference of 4.25 g/m2 (95% CI, 2.08, 6.42) and 0.03
(95% CI, 0.01, 0.05), respectively. In comparison with the nonpreeclampsia population, they also demonstrated a lower E/A and a
higher E/e0 ratio with a mean difference of 0.08 (95% CI, 0.15, 0.01) and 0.84 (95% CI, 0.41, 1.27), respectively.
Conclusions-—In comparison with women who had a normotensive pregnancy, women with a history of preeclampsia
demonstrated a trend toward altered cardiac structure and function. Further studies with larger sample sizes and consistent
echocardiogram reporting with the use of sensitive preclinical markers are required to assess the role of echocardiography in
monitoring this high-risk population group. ( J Am Heart Assoc. 2019;8:e013545. DOI: 10.1161/JAHA.119.013545.)
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P reeclampsia is a heterogenous disorder of pregnancy thataffects 3% to 5% of women and is characterized by a final
common pathway of endothelial dysfunction resulting in hyper-
tension and end-organ damage.1,2 The underlying etiology of
preeclampsia is unclear, and there is increasing evidence to
support that there are different pathophysiological subtypes of
this disease.3,4 These subtypes include: (1) the characteristic
placental mediated disorder that results in placental ischemia
and the release of antiangiogenic factors into the maternal
circulation and (2) a syndromewhere preeclampsia is a symptom
of underlying vascular dysfunction and a failure of the physio-
logical stress test of pregnancy.3 The latter in particular is now
supported by epidemiological evidence that preeclampsia does
not resolvewithdelivery of the placenta, but, rather, is associated
with an increased risk of long-term cardiovascular sequelae.5 For
example, 20% of women with preeclampsia remain hypertensive
at 6 months postpartum, and these women have a 3-fold
increased risk of chronic hypertension.6,7 A recent systematic
review of 22 studies also illustrated that a history of
preeclampsia is associated with a 2- to 4-fold increased risk of
heart failure, coronary artery disease, stroke, and cardiovascular
disease–related death.5 The American Heart Association has
now recognized both gestational hypertension and preeclampsia
as risk factors for cardiovascular disease.8,9 However, it is
unclear whether increased cardiovascular morbidity is a result of
shared risk factors between preeclampsia and cardiovascular
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disease or a direct result of the hypertensive disorder of
pregnancy.10 There is also insufficient evidence or consensus
regarding the most appropriate method and timing of cardio-
vascular monitoring within this population group.
Transthoracic echocardiography is the gold standard for
noninvasive evaluation of cardiac structure and function.
However, there is little research examining the use of
echocardiography to assess cardiovascular risk in women with
a history of preeclampsia. The studies that have been
conducted are limited by small sample sizes and have reported
inconsistent results. Significant limitations to postpartum
follow-up studies in preeclampsia include the low incidence of
disease, heterogeneity of the population group, and significant
loss to follow-up. With this in mind, a systematic review and
meta-analysis may be of benefit in identifying potential
structural and functional changes to the cardiovascular system
in women with a history of preeclampsia.
With this review, we aimed to determine whether women
with a history of preeclampsia show clinical or subclinical
cardiac changes when evaluated by echocardiography. We
hypothesize that women with a history of preeclampsia
demonstrate altered cardiac function in comparison with
those with a history of normotensive pregnancies. Identified
associations between echocardiogram abnormalities and




This systematic review is registered with PROSPERO (The
International Prospective Register of Systematic Reviews; ID,
CRD42018115554) and conducted in accord with the MOOSE
(Meta-analysis of Observational Studies in Epidemiology)
guidelines (Table S1). There was no deviation from the
original protocol submitted to PROSPERO, and the authors
declare that all supporting data are available within the article
and its online supplementary files.
We performed a systematic search of MEDLINE, EMBASE,
and CINAHL databases from inception to December 2018.
The search strategy, described in detail in Table S2, focused
on identifying studies that examined cardiac function in
women with a history of preeclampsia in comparison with
those with normotensive pregnancies. The reference lists of
the included articles and other published reviews were also
examined to identify additional relevant studies for this
review. Both librarians and investigators were involved in
developing the search strategy.
Inclusion and Exclusion Criteria
Studies were included if they assessed cardiac structure and
function in women with a history of preeclampsia at >6 weeks
postpartum using echocardiography. Studies were excluded if:
(1) cardiac assessments were performed within 6 weeks of
delivery; (2) detailed assessment of cardiac structure and
function by echocardiography was not performed; (3) the timing
of echocardiography was not reported; (4) no matched nor-
motensive pregnancies were evaluated as part of the study; (5)
the study evaluated gestational hypertensives only; or (6) the
manuscript was not available for review in English or only
available in abstract form. The decision to exclude conference
abstracts was based on the: (1) limitations in assessing study
quality of conference abstracts alone and (2) difficulty in
extracting the required depth of information fromsuch abstracts.
Studies that assessed cardiac function within 6 weeks of
delivery were excluded because of the known hemodynamic
changes that occur in the immediate postpartum period.
Study Selection
Two reviewers (M.R., L.W.) independently screened the titles and
abstracts and excluded articles that were irrelevant to the topic.
The reviewers then evaluated the full text of eligible articles for
suitability based on the strict inclusion and exclusion criteria. A
third reviewer (D.L.R.) was used to resolve discrepancies.
Data Extraction
The research question, study design, patient demographic
data, and cardiac indices reported in each study were
recorded. Cardiac indices of interest were identified according
to the American Society of Echocardiography and European
Association of Cardiovascular Imaging Guidelines.11,12 For
evaluation of diastolic function, the 2009 American Society of
Clinical Perspective
What Is New?
• Women with a history of preeclampsia have an increased
left ventricular mass index, increased relative wall thick-
ness, lower E/A ratio, and higher E/e0 ratio in comparison
with those with a history of normotensive pregnancies.
• Given that women with a history of preeclampsia demon-
strate altered cardiac structure and function preceding the
development of cardiovascular disease, echocardiography
may play an important role in the ongoing evaluation of this
high-risk population group.
What Are the Clinical Implications?
• Further research with larger sample sizes, consistent report-
ing, and assessment of sensitive preclinical markers, such as
myocardial deformation, is required to clarify these findings.
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Echocardiography/European Association of Cardiovascular
Imaging guidelines were used, given that a significant
proportion of the studies were performed before the release
of the new 2016 guidelines. Indices assessed included left
ventricular mass index (LVMI), relative wall thickness (RWT),
left ventricular ejection fraction (LVEF), mean E/A ratio, mean
E/e0 ratio, isovolumetric relaxation time, and deceleration
time. These indices were chosen because they are key to
assessing cardiac morphology, systolic function, and diastolic
function and are further defined in Table 1.12,13
Quality Assessment
Quality assessment was performed by 2 independent blinded
authors (M.R., D.L.R.) using the Newcastle–Ottawa Scale for
cohort studies.14 Risk of bias was analyzed within the 3
categories of case selection, comparability between cases
and controls, and outcome. A study was considered good
quality if it obtained ≥3 points in the selection domain, ≥1
point in the comparability domain, and ≥2 points in the
outcome domain. A study was considered fair quality if it
obtained 2 points in the selection domain, ≥1 point in the
comparability domain, and ≥2 in the outcome domain. A study
was assessed as poor quality if it obtained a score of 0 to 1 in
the selection domain, a score of 0 in the comparability
domain, or a score of 0 to 1 in the outcome domain.15
Statistical Analysis
Data regarding the variables of interest were extracted from
each study for the preeclampsia and nonpreeclampsia groups.
The primary outcome was the mean difference (MD) between
the preeclampsia and nonpreeclampsia groups in relation to
various cardiac indices. Most studies reported the data as a
continuous variable using mean and SD. To ensure consis-
tency and allow for aggregation of results, when the central
tendency and the spread of the distribution were reported
respectively as median and interquartile range (IQR), mean
Table 1. Cardiac Indices Assessed and Their Implications as Identified by the American Society of Echocardiography and European
Association of Cardiovascular Imaging12,13
Cardiac Indices Definition/Measurement Method Normal Ranges Implications
LVMI, g/m2 Measured at the end of diastole using, linear method,
2D echocardiography, or 3D echocardiography and
indexed to body surface area.
Linear measurement: 43 to 95
2D measurement:
44 to 88
Increased LVMI suggests hypertrophy.
The type of hypertrophy (eccentric or
concentric) is determined by the RWT.
RWT Calculated using the formula -
RWT=(29posterior wall thickness)/(LV internal
diameter at end diastole)
RWT>0.42
RWT≤0.42
RWT>0.42 suggests concentric remodeling.
RWT≤0.42 suggests eccentric remodeling.
LVEF Ejection fraction is calculated through measurement of
end-diastolic velocity (EDV) and end-systolic velocity
(ESV).
EF = (EDV-ESV)/EDV
53% to 73% Reduced ejection fraction is suggestive of
systolic dysfunction.
E/A ratio The mitral E/A ratio is made up of 2 components which
reflect the pressure gradient between the left atria and
ventricle during early and late diastole.
E wave: Early diastole is characterized by rapid flow
across the mitral valve resulting in a peak in flow
called the E wave.
A wave: The “a wave” reflects increased filling
velocities in late diastole attributed to an atrial
contraction.
0.8 to 2.0* The E/A ratio in combination with DT and
IVRT can be used to identify LV filling
patterns that are suggestive of diastolic
dysfunction.
Mild diastolic dysfunction
Characterized by decreased E/A ratio,
prolonged DT, and prolonged IVRT.
Pseudo-normal phase
E/A ratio, DT and IVRT return to within
normal range. Increased E/e0 ratio and a
decrease in E/A ratio with Valsalva
maneuver.
Severe dysfunction with restrictive filling
pattern
Characterized by increased E/A ratio, shortened
DT, and IVRT.
DT Interval between the peak of the E wave to the
beginning of diastasis. Diastasis refers to the period
where flow across the mitral valve decreases as a
result of rising ventricular pressures. Deceleration
time is influenced by LV relaxation and stiffness.
140 to 200 ms*
IVRT Time between closure of the aortic valve at the end of
systole to the opening of the mitral valve at the
beginning of diastole.
70 to 100 ms*
Mean E/e0 ratio Ratio of flow across the mitral valve through early
diastole (the E wave) and the mitral annular early
diastolic velocity (e0 wave).
E/e0<8=normal
E/e0>14=abnormal
An elevated E/e0 ratio is indicative of raised
LV filling pressures.
DT indicates deceleration time; IVRT, isovolumetric relaxation time; LV, left ventricular; LVMI, left ventricular mass index; RWT, relative wall thickness.
*With increasing age E/A ratio decreases, and DT and IVRT increase. Therefore, age-specific ranges must be used.
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and SD were estimated according to the method devised by
Hozo et al.16 In order to assess the potential influence of data
transformation on analysis, a sensitivity analysis was per-
formed with the exclusion of studies that used median/IQR.
MD and a random-effects model was used to compare the
difference in cardiac indices between preeclampsia and
nonpreeclampsia groups. A random-effects model was used
in preference to a common effect size, given that the studies
included in the analysis were observational studies with
different population groups.
Publication bias was assessed with funnel plot symmetry.
The presence or absence of heterogeneity was determined
using the chi-square test, and the magnitude of heterogeneity
was assessed with the I2 statistic. Heterogeneity was
considered to be present when the chi-square test revealed
a P<0.05 and the magnitude of heterogeneity considered to
be low, moderate, and high with an I2 statistic of <25%, 50%,
and >75%, respectively.17 When high heterogeneity (I2>75%)
was identified, a subgroup analysis was performed to suggest
potential sources of heterogeneity. The demographic and
study characteristics assessed in the subgroup analysis
included sample size, quality of study, age at assessment,
time from index pregnancy, and body mass index (BMI). A
subgroup analysis was also performed to assess the influence
of the method of data reporting (mean/SD or median/IQR) on
heterogeneity. The analysis was performed using Review
Manager 5.3 (RevMan, version 5.3.5; The Cochrane collabo-
ration, 2014).
Results
Study and Data Selection
The electronic search of MEDLINE, EMBASE, and CINAHL
databases identified 3456 potential studies (Figure 1). After
the removal of duplicates, 2839 articles were screened for
eligibility. Subsequently, 2778 publications were excluded
through screening of titles and abstracts. The full text of the
remaining 61 articles was assessed for eligibility, and, of
those, 34 studies were excluded because of: (1) single-arm
study (n=8); (2) assessment within 6 weeks of delivery (n=5);
(3) no or minimal echocardiogram data (n=8); (4) uncertain
echocardiogram results (n=1); (5) duplicate reporting (n=6);
(6) assessment of participants with gestational hypertension
only (n=4); and (7) wrong study design (n=2). Of the 27
studies included, a further 2 studies were excluded from the
meta-analysis because they did not provide data regarding the
echocardiogram variables of interest. One study assessed
cardiac function at 1 and 14 years postpartum, and another
assessed those with a history of early and late preeclampsia
as separate groups. Thus, within these studies, the subgroups
were analyzed as separate entities.
Quality Assessment
Nine studies (33%) were considered high quality, 1 (4%) fair
quality, and 17 (63%) poor quality (Table S3). Most studies
performed well in the domain of cohort selection and were
representative of the preeclampsia and normotensive popu-
lation in the community. With regard to comparability of
cohorts, 41% of the studies failed to control for important
factors such as age, BMI, and smoking. Most studies did not
blind echocardiogram assessment to disease exposure, and
63% failed to report or had inadequate follow-up.
Study Characteristics
Study characteristics and demographic data are illustrated in
Table 2.18–44 A total of 5058 women were reviewed beyond
pregnancy, of which 1797 had a history of preeclampsia.
The majority of studies defined preeclampsia using the
traditional criteria of hypertension and proteinuria after
20 weeks of gestation. Few studies (n=3) utilized the
updated definition of hypertension with evidence of end-
organ dysfunction. With regard to superimposed preeclamp-
sia, a large proportion of the studies excluded women with
pre-existing hypertension, diabetes mellitus, and renal
disease (n=15). Of the remaining, the addition of proteinuria
or end-organ dysfunction was required to confirm the
diagnosis of preeclampsia.
In the preeclampsia group, cardiac function was assessed
within 12 months of delivery in 11 studies (41%), between
12 months and 5 years in 7 studies (26%), between 5 and
10 years in 1 study (4%), and >10 years from the index
pregnancy in 7 studies (26%). In the nonpreeclampsia group,
cardiac function was assessed within 12 months of delivery in
11 studies (41%), between 12 months and 5 years in 6 studies
(22%), between 5 and 10 years in 2 studies (7%), >10 years in 6
studies (22%), and was not reported in 1 study (4%). Further-
more, 1 study assessed cardiac function at both 1 and 14 years
postpartum in both preeclampsia and nonpreeclampsia groups.
The mean age of assessment was <50 years in 23 of 27
(85%) and 24 of 27 studies (89%) in the preeclampsia and
nonpreeclampsia groups, respectively. Two studies assessed
women at a mean age >50 years in both the preeclampsia and
nonpreeclampsia groups. Two studies did not report age of
assessment in the preeclampsia group, and 1 study did not
report age of assessment in the nonpreeclampsia group. Of the
24 studies (89%) that reported BMI, themean BMIwas normal in
42% of the studies in the preeclampsia group and 71% of the
studies in the nonpreeclampsia group. Three studies reported a
mean BMI≥30 kg/m2 in the preeclampsia group, and 1
reported a mean BMI≥30 kg/m2 in the nonpreeclampsia
group. Mean arterial pressure was reported in 25 of 27 studies
(93%). Most studies reported a normal mean arterial pressure of
DOI: 10.1161/JAHA.119.013545 Journal of the American Heart Association 4
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<100 mm Hg in both the preeclampsia and nonpreeclampsia
groups. A mean mean arterial pressure of ≥100 mm Hg was
reported in 4 studies in the preeclampsia group and 2 studies in
the nonpreeclampsia group.
With regard to cardiovascular risk factors, most studies
either excluded or did not report cardiovascular risk factors
(Table S4). Of the studies that included women with cardiovas-
cular risk factors, hypertension was more common in the
preeclampsia group in comparison with the nonpreeclampsia
group. The rate of current or past smoking was similar in both
groups. Few studies included or reported the presence of
diabetes mellitus, renal disease, or cardiovascular disease at
the time of evaluation.
Furthermore, 3 studies within the preeclampsia group
included participants with a history of gestational hyperten-
sion or preeclampsia. Two of the 3 studies reported that the
majority of participants were identified to have preeclampsia,
and 1 did not report this information. Analysis was performed
with inclusion and exclusion of these studies and showed no
difference in results (data not presented).
Left Ventricular Mass Index
LVMI was assessed in 19 of 27 studies (70%). LVMI was
significantly higher in those with a history of preeclampsia in
comparison with those with normotensive pregnancies (MD,
Data presented did not examine variables of interest (n=2)
Titles and abstracts screened (n=2839)












- Commentaries, correspondence, case reports and
reviews (n=334)
- Studies not relevant to research quesons (n=1711)
- Studies assessing cardiac funcon pre-pregnancy,
antenatally, or within six weeks postpartum (n=253)
- Peripartum cardiomyopathy (n=224)
- Studies assessing fetal/neonatal/childhood cardiac f(x)
(n=113)
- Studies that did not assess women with preeclampsia,
did not include controls, or did not use
echocardiography for assessment (n=64)
- Animal studies (n=44)
- Duplicate studies (n=21)
- Conference abstracts only (n=12).













Single arm study (n=8)
Duplicate reporng (n=6)
Inadequate echocardiogram measurements (n=8)
Uncertain echocardiogram results (n=1)
Within six weeks postpartum (n=5)
Wrong study design (n=2)
Assessed gestaonal hypertensives only (n=4)
Included studies (n=27)
Full text arcles assessed for eligibility (n=61)






Figure 1. PRISMA flowchart of study selection process.
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4.25 g/m2; 95% CI, 2.08–6.42; P=0.0001; Figure 2A).19,20,22–
26,29–37,39,42,44 While there was no evidence of funnel plot
asymmetry suggesting publication bias (Figure S1), the hetero-
geneity between studies was significant (I2=93%; P<0.00001).
Subgroup analysis to determine the source of heterogeneity
showed that study quality, sample size, age of assessment, BMI,
and time from index pregnancy did not reduce heterogeneity.
However, when studies that required transformation of median/
IQR were removed from analysis, heterogeneity reduced from
high to moderate (I2=50%; P=0.02). LVMI remained significantly
higher in women with a history of preeclampsia despite the
removal of these studies from analysis (MD, 3.85 g/m2; 95% CI,
1.79–5.91; P=0.0003).
Relative Wall Thickness
RWT was reported in 13 of 27 studies (48%). The pooled
RWT was marginally higher in women with a history of
preeclampsia in comparison with those with normotensive
pregnancies (MD, 0.03; 95% CI, 0.01–0.05; P=0.02;
Figure 2B).19,23,26,29–35,37,42,44 When we performed a sensi-
tivity analysis and removed studies that reported data as
median/IQR, we identified no differences in RWT between
groups (MD, 0.01; 95% CI, 0.01–0.04; P=0.26). There was
no evidence of funnel plot asymmetry to suggest publica-
tion bias (Figure S1). Again, there was significant hetero-
geneity between studies (I2=94%; P<0.00001). Subgroup
analysis did not reduce heterogeneity when assessed for
method of data reporting (mean/SD or median/IQR),
sample size, study quality, age at assessment, time from
index pregnancy, and BMI.
Left Ventricular Systolic Function
Most studies assessed systolic function using LVEF. LVEF was
reported in 19 of 27 studies (70%), and all studies reported a
normal mean ejection fraction in both the preeclampsia and
nonpreeclampsia groups. There were no differences in LVEF
between women with a history of preeclampsia and nor-
motensive pregnancies (MD, 0.69%; 95% CI, 1.77–0.38;
P=0.21; Figure 3).19–25,27,29,31–33,35,36,38,39,41,43,44 There
was no evidence of funnel plot asymmetry to suggest
publication bias (Figure S1). However, there was heterogene-
ity between studies (I2=86%; P<0.00001). A subgroup and
sensitivity analysis showed that when studies that reported
median/IQR were removed, women with a history of
preeclampsia had a lower LVEF (MD, 1.05%; 95% CI,
1.92 to 0.18; P=0.02). Furthermore, heterogeneity
between studies improved from high to moderate (I2=51%;
P=0.01). Subgroup analysis did not suggest any difference
in heterogeneity when assessed for sample size, study
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Left Ventricular Diastolic Function
The most common diastolic parameters reported were E/e0
ratio, E/A ratio, isovolumetric relaxation time, and DT. The
E/e0 ratio was reported in 11 of 27 studies (41%) and was
higher in women with a history of preeclampsia in compar-
ison with normotensive pregnancies (MD, 0.84; 95% CI,
0.41–1.27; P=0.0001; Figure 4A).19,22,24,25,29,32,33,36,38,41,42
The E/A ratio was reported in 18 of 27 studies (67%) and
was lower in women with a history of preeclampsia in
comparison with normotensive pregnancies (MD, 0.08;
95% CI, 0.15 to 0.01; P=0.03; Figure 4B).19–23,25,29,30,32–
36,38–41,44 In the 11 studies (41%) that assessed
isovolumetric relaxation time, there was no difference in
measurements between the preeclampsia and nonpree-
clampsia groups (MD, 0.52 ms; 95% CI, 4.30–5.30;
P=0.83; Figure S2). Similarly, in the 15 studies (56%) that
assessed deceleration time, there was no difference in
measurements between the preeclampsia and nonpree-
clampsia groups (MD, 1.50 ms; 95% CI, 4.56–7.55;
P=0.63; Figure S3). Funnel plot symmetry revealed no
evidence of publication bias across all diastolic indices
(Figure S1). However, there was significant heterogeneity
between studies in all diastolic indices, with the I2 statistic
ranging from 85% to 95%. Across all diastolic indices,
subgroup analysis of sample size, method of data reporting,
Figure 2. Forest plot illustrating the mean difference in indices of left ventricular hypertrophy. A, Mean difference in left ventricular mass
index (g/m2) between PE and non-PE groups. (B) Mean difference in relative wall thickness between PE and non-PE groups. *Data transformed
from median and IQR to mean and SD. **Data originally reported as mean and standard error. ***Data originally reported as geometric mean
and SD. IQR indicates interquartile range; PE, preeclampsia.
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study quality, mean age at assessment, time from index
pregnancy, and BMI did not reduce heterogeneity.
Discussion
Despite epidemiological evidence of increased cardiovascular
risk in women with a history of preeclampsia, postpartum
evaluation has not been widely implemented. This is in
contrast to other pregnancy conditions, such as gestational
diabetes mellitus, where because of an increased risk of type
2 diabetes mellitus, it is recommended that women undergo
glycemic testing every 1 to 3 years after delivery.45,46
Unfortunately, widespread implementation of cardiovascular
screening in the setting of preeclampsia is limited by an
inadequate understanding of the mechanisms that cause
cardiovascular disease in this population group. To our
knowledge, this systematic review is the first to describe
changes to cardiac structure and function in women with a
history of preeclampsia. When compared with normotensive
pregnancies, women with a history of preeclampsia have a
higher LVMI, higher RWT, lower E/A ratio, and higher E/e0
ratio. These findings are highly relevant, in that they add to
the body of evidence that preeclampsia is associated with
persisting cardiovascular dysfunction and support the need
for closer monitoring of this high-risk population group.
However, we have also identified a need to study more-robust
markers of early cardiac disease, such as myocardial defor-
mation and exercise capacity, to aid in clinical decision
making in these high-risk women.25,47,48
During pregnancy, women with preeclampsia have evi-
dence of cardiac remodeling and a difference in cardiac
function in comparison with those with normotensive preg-
nancies.49,50 Systematic reviews by De Haas et al and
Castleman et al have shown that antenatally, preeclampsia
is associated with increased left ventricular mass and RWT
and mild diastolic dysfunction (as demonstrated by a
decrease in the E/A ratio and an increase in the E/e0
ratio).49,50 Long-term epidemiological studies have shown
that women with a history of preeclampsia have a 2- to 4-fold
increased risk of heart failure and cardiovascular morbidity.5
Thus, it is assumed that the structural and functional changes
observed antenatally persist beyond pregnancy and con-
tribute to the long-term cardiovascular sequelae in this
population group. However, while our review supports this
hypothesis, the findings suggest that the echocardiogram
changes following delivery are perhaps too subtle to explain
the longer-term morbidities. This may be attributable to
several reasons.
First, a large proportion of the studies excluded women
with hypertension, diabetes mellitus, renal disease, and
cardiovascular disease. Women with such pre-existing comor-
bidities are at a greater risk of developing preeclampsia.51,52
Furthermore, women with a history of preeclampsia are more
likely to develop hypertension, metabolic syndrome, renal
disease, and diabetes mellitus in the long term.6,53–56 It is
thus plausible that the cardiovascular morbidity associated
with preeclampsia is a result of an increased incidence of
these cardiovascular risk factors within this population group
rather than the preeclampsia per se. Exclusion of these risk
Figure 3. Forest plot illustrating the mean difference in left ventricular ejection fraction (%) in PE and non-PE groups. *Data transformed from
median and IQR to mean and SD. IQR indicates interquartile range; PE, preeclampsia.
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factors may have contributed to selection bias and may have
influenced the results of the constituent trials included in this
review. It is also plausible that the cardiovascular sequelae
observed in those with a history of preeclampsia are a result
of shared risk factors between preeclampsia and cardiovas-
cular disease.57 Therefore, when women with cardiovascular
risk factors are excluded, the effect of preeclampsia on
cardiac structure, function, and morbidity may be clinically
insignificant. Further studies which compare pre-eclamptic
women with and without cardiovascular risk factors are
required in order to answer this clinical question.
Second, the available studies included in this review are of
small sample size and significant heterogeneity. It is likely
that the heterogeneity stems from the inherent limitations of
cohort studies which cannot control for all demographic
factors within the population assessed. While a random-
effects model and subgroup analyses were performed in order
to account for such differences, this did not significantly
improve heterogeneity measures. Potential methods of
addressing this in future research would include larger sample
sizes and consistent reporting of patient demographics and
echocardiogram measures. Limitations to performing large
studies in women with a history of preeclampsia include the
low incidence of disease and significant loss to follow-up.
Thus, international collaboration is essential. Standardization
and consistent reporting of echocardiogram measurements is
also vital. The American Society of Echocardiography and the
European Association of Cardiovascular Imaging provide clear
guidelines on methods of measurement of cardiovascular
indices to assess chamber size, systolic function, and diastolic
Figure 4. Forest plot illustrating the mean difference in indices of diastolic function. A, Mean difference in E/e0 ratio between PE and non-PE
groups; B, Mean difference in E/A ratio between PE and non-PE groups. *Data transformed from median and IQR to mean and SD. **Data
originally reported as mean and standard error. ***Data originally reported as geometric mean and SD. IQR indicates interquartile range; PE,
preeclampsia.
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function.11,12 These guidelines now include the use of 4
markers to catagorize diastolic dysfunction—average E/e0,
septal e0 velocity, lateral e0 velocity, tricuspid regurgitation
velocity, and left atrial volume index.58 This increases the
sensitivity for prediction of left ventricular filling pressures
over using markers in isolation.58 The studies included in this
review did not evaluate the newly included tricuspid regurgi-
tation maximum velocity, and very few assessed volumetric
measures of left atrial size. Unfortunately, this limits our
ability to apply the new guidelines in this cohort. Adopting
these guidelines may reduce heterogeneity and allow for
easier comparison between different cohort studies examin-
ing cardiac function in women with a history of preeclampsia.
It is also important to note that many of the included
studies performed poorly with regard to quality assessment.
Primary issues included a lack of blinding for outcome,
controlling for confounding factors, and loss to follow-up.
These quality issues make it difficult to draw meaningful
conclusions. As a result, it is essential that while also
addressing heterogeneity, future research efforts focus on
robust methodology with adequate blinding of echocardio-
gram assessors and reporting of loss to follow-up. Further-
more, it is necessary that confounding factors, such as age,
BMI, smoking, and other cardiovascular risk factors, are
reported and considered in analysis. Although out of the
scope of this review, there is also a need for an individual
patient data meta-analysis. This may help address issues with
heterogeneity and confounding. Furthermore, an individual
patient data would enable a detailed review of the echocar-
diogram markers and allow for both categorical and
continuous analysis of cardiac indices. This would shed light
on whether the differences between preeclampsia and
nonpreeclampsia groups are within the variation of normal
or a true reflection of a higher incidence of abnormal results.
Last, it is also plausible that grading of diastolic dysfunc-
tion may not be the ideal method of risk stratification in
women with a history of preeclampsia. Invasive studies have
shown only modest correlations of E/e0 ratio and invasive
filling pressures.59 The measurement of global myocardial
deformation using speckle tracking imaging is a novel marker
that can be performed during routine echocardiographic
assessment. It has been demonstrated that global longitudinal
strain is a robust marker of cardiac outcomes and incremental
to other echocardiogram parameters for prediction of out-
comes in stage B heart failure.47 A small number of studies
have used global longitudinal strain in preeclampsia cohorts
and observed reduced strain in preeclampsia as compared
with normotensive pregnancies.25,48 Furthermore, the differ-
ences between women with and without a history of
preeclampsia in this systematic review are analogous to
hypertensive heart disease and are relatively subtle. Global
longitudinal strain has proved to be an important prognostic
marker of cardiovascular events in the general population and
in hypertensive cohorts,60,61 suggesting that this may be a
logical investigative tool for future research. An overlooked,
but essential, parameter is a clear definition of exercise
capacity. When combined with echocardiography, cardiopul-
monary exercise testing can aid in the identification of stage B
heart failure,62 and reduced exercise capacity has been shown
to be one of the strongest predictors of heart failure and
premature mortality.63–65 Further research is required to
delineate whether a combination of structural evaluation of
cardiac function and exercise capacity is necessary to
determine risk of cardiovascular sequelae in pre-eclamptic
women.
Nonetheless, the findings of this study support that women
with a history of preeclampsia have persisting cardiac
dysfunction, and further efforts should be directed at
identifying the most appropriate method of monitoring these
high-risk women. Furthermore, it is important to investigate
whether, once identified, intervention within this high-risk
group improves outcomes. It is plausible that early detection
and treatment of hypertension, diabetes mellitus, and renal
disease with lifestyle and pharmacological measures will alter
cardiovascular risk in women with a history of preeclampsia.
This, however, has not been investigated. Interestingly,
studies have demonstrated that an awareness of the prob-
ability of developing cardiovascular disease influences behav-
ior modification in those with a history of preeclampsia.66
Thus, empowering patients with such information may, on its
own, trigger the necessary lifestyle changes to improve
cardiovascular outcomes. There is also considerable evidence
to demonstrate that progression from asymptomatic to
symptomatic heart failure is associated with a 5-fold increase
in mortality.67 Early identification of asymptomatic heart
failure and implementation of lipid management and blood
pressure control have been shown to reduce the risk of
progression to symptomatic disease.67 There are no studies
to date that have addressed the role of monitoring and early
intervention in women with a history of preeclampsia, and it is
certainly an important area of future research.
Conclusions
Women with a history of preeclampsia demonstrate altered
cardiac structure and evidence of diastolic function, which
may then translate to an increased risk of long-term
cardiovascular sequelae. However, the ideal method of
monitoring and risk stratification in this high-risk group
remains elusive. Further research with larger sample sizes,
consistent reporting, and assessment of sensitive preclinical
markers, such as myocardial deformation, are required in
order to clarify these findings.
DOI: 10.1161/JAHA.119.013545 Journal of the American Heart Association 11
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Database Search Strategy 
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hypertension). OR . ("eclampsia" or "HELLP syndrome").mp. 
AND 
exp Echocardiography/ OR exp Ventricular Function/ OR exp Heart 
Ventricles/ OR exp Ventricular Dysfunction/ ORexp Heart Failure/ OR 
echocardiogra*.mp. OR ("systolic function*" or "diastolic function*").mp. OR 
("diastolic dysfunction" or "systolic dysfunction").mp. OR ("ventricular 
remodelling" or "ventricular remodeling").mp. 
[mp=title, abstract, original title, name of substance word, subject heading 
word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms]  
EMBASE exp preeclampsia/ or exp "eclampsia and preeclampsia"/ OR exp maternal 
hypertension/ OR (preeclampsia or pre-eclampsia) OR gestation* 
hypertension.mp. OR (pregnancy adj2 hypertension).mp. OR ("eclampsia" or 
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exp echocardiography/ OR exp heart function/ IR exp heart failure/ 
OR echocardiogra*.mp. OR ("systolic function*" or "diastolic function*") OR 
("diastolic dysfunction" or "systolic dysfunction").mp. OR ("ventricular 
remodelling" or "ventricular remodeling").mp.  
[mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
CINAHL (MW preeclampsia OR pre-eclampsia OR eclampsia OR hypertension in 
pregnancy OR gestational hypertension OR pregnancy induced hypertension 
OR maternal hypertension) OR (preeclampsia OR pre-eclampsia OR 
gestation* hypertension OR pregnancy adj2 hypertension OR eclampsia OR 
“HELLP syndrome”) 
AND  
(MW echocardiography OR ventricular function OR ventricular dysfunction 
OR heart failure) OR (echocardiog* OR “systolic function” OR “diastolic 
function” OR “systolic dysfunction” OR “diastolic dysfunction” OR 
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Table S3. Quality assessment using the Newcastle Ottawa Scale. 
Study 
Selection  
(Total score - 4) 
Comparability  
(Total score - 2) 
Outcome 
(Total score - 3) 
Total Quality 
Abdel Wahab (2018)2 3 1 1 5 Poor 
Al-Nashi (2016)3 4 1 2 7 High 
Andrietti (2008)4 1 0 1 2 Poor 
Atalla (2015)5 4 1 2 7 High 
Bokslag (2018)6 4 1 2 7 High 
Breetveld (2018)7 4 0 1 5 Poor 
Ciftci (2014)8 1 2 2 5 Poor 
Clemmensen (2018)9 3 1 2 6 High 
Collen (2013)10 2 1 2 5 Fair 
Estensen (2013)11 1 0 2 3 Poor 
Evans (2011)12 3 0 2 5 Poor 
Ghi (2014)13 3 1 1 5 Poor 
Ghossein-Doha (2013)14 1 0 1 2 Poor 
Ghossein-Doha (2017)15 2 0 2 4 Poor 
Melchiorre (2011)16 3 1 2 6 High 
Orabona (2017)17 4 1 2 7 High 
Rafik Hamad (2009)18 4 1 1 6 Poor 
Scantlebury (2015)19 1 0 3 4 Poor 
Shahul (2018)20 4 1 3 8 High 
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Soma-Pillay (2018)22 3 0 2 5 Poor 
Spaan (2009)23 3 1 1 5 Poor 
Strobl (2011)24 3 0 2 5 Poor 
Tyldum (2012)25 4 0 1 5 Poor 
Valensise (2016)26 3 1 2 6 High 
Yu (2018)27 3 0 1 4 Poor 













PE No-PE PE No-PE PE No-PE PE No-PE PE No-PE 
Abdel Wahab (2018)2 Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded 
Al-Nashi (2016)3 1 (7) 0(0) 0(0) 1 (6) 0(0) 0(0) NR NR 0(0) 0(0) 
Andrietti (2008)4 NR NR NR NR NR NR NR NR NR NR 
Atalla (2015)5* Excluded Excluded NR NR Excluded Excluded Excluded Excluded Excluded Excluded 
Bokslag (2018)6 50 (38) 8 (14) 23 (18) 9 (16) NR NR NR NR NR NR 
Breetveld (2018)7 10 (15) 1 (3) 5 (7) 3 (8) 3 (4) 0 (0) NR NR NR NR 
Ciftci (2014)8 Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded 
Clemmensen (2018)9 13 (25) 6 (15) 19 (36) 17 (43) 3 (6) 1 (3) NR NR NR NR 
Collen (2013)10 25 (50) 17 (31) NR NR 3 (12) 0 (0) NR NR NR NR 
Estensen (2013)11* NR Excluded 6 (8) 0 (0) NR Excluded NR Excluded NR Excluded 
Evans (2011)12 NR NR Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded 
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Ghi (2014)13 Excluded Excluded Excluded Excluded NR NR NR NR Excluded Excluded 
Ghossein-Doha (2013) - 
1year14 
3 (15) 0 (0) 2 (10) 1 (13) NR NR NR NR NR NR 
Ghossein-Doha (2013) – 
14 years14 
7 (35) 1 (13) 1 (5) 3 (38) NR NR NR NR NR NR 
Ghossein-Doha (2017)15 25 (23) 1 (2) 8 (7) 5 (12) 1 (1) 0 (0) NR NR NR NR 
Melchiorre (2011)16 NR NR NR NR NR NR NR NR NR NR 
Orabona (2017)17 Excluded Excluded Excluded Excluded Excluded Excluded NR NR Excluded Excluded 
Rafik Hamad (2009)18 NR NR Excluded Excluded NR NR NR NR NR NR 
Scantlebury (2015)19 294 (69) 1164 (53) 111 (26) 631 (29) 151 (35) 614 (28) NR NR NR NR 
Shahul (2018)20* 7 (22) 1 (4) NR NR Excluded Excluded NR NR Excluded Excluded 
Simmons (2002)21* Excluded Excluded NR Excluded Excluded Excluded Excluded Excluded Excluded Excluded 
Soma-Pillay (2018)22 52 (54) 2 (4) NR NR 6 (6) 0 (0) NR NR NR NR 
Spaan (2009)23 12 (55) 2 (7) 3 (14) 10 (35) Excluded Excluded Excluded Excluded 2 (9) 1 (3) 
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Tyldum (2012)25* Excluded Excluded 1(5) 2 (10) Excluded Excluded NR NR Excluded Excluded 
Valensise (2016)26 Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded Excluded 
Yu (2018)27* Excluded Excluded Excluded Excluded NR NR NR NR Excluded Excluded 
Yuan (2014)28* Excluded Excluded Excluded Excluded Excluded Excluded NR NR NR NR 
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Left Ventricular Mass Index Relative Wall Thickness 
Left Ventricular Ejection Fraction E/e’ Ratio 
E/A Ratio Isovolumetric Relaxation Time 
Deceleration Time 
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C) Mean difference in isovolumetric relaxation time (ms) between PE and non-PE 
groups 
* Data transformed from median and IQR to mean and SD
** Data originally reported as mean and standard error 
Figure S2. Forest plot illustrating the mean difference in isovolumetric relaxation time (ms) 
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* Data transformed from median and IQR to mean and SD
** Data originally reported as mean and standard error 
*** Data originally reported as geometric mean and SD 
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